Literature DB >> 12120255

Selective anticancer drugs.

Joshua H Atkins1, Leland J Gershell.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12120255     DOI： 10.1038/nrd842

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  15 in total

Review 1.  [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Authors:  P A Gerber; B A Buhren; S Kürle; B Homey
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

2.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Pharmaceutical differences between block copolymer self-assembled and cross-linked nanoassemblies as carriers for tunable drug release.

Authors:  Hyun Jin Lee; Younsoo Bae
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

4.  Photo-inducible crosslinked nanoassemblies for pH-controlled drug release.

Authors:  Matthew Dickerson; Nickolas Winquist; Younsoo Bae
Journal:  Pharm Res       Date:  2013-11-20       Impact factor: 4.200

5.  Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.

Authors:  Ali R Jazirehi; Peter B Wenn; Mohsen Damavand
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

6.  B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.

Authors:  Xishan Xiong; Yingwei Zhang; Xiang Gao; Zheyi Dong; Lin Li; Chengcheng Ji; Lili Fu; Xiaomin Luo; Hong Liu; Changlin Mei
Journal:  Invest New Drugs       Date:  2009-01-13       Impact factor: 3.850

Review 7.  Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Authors:  Christine Victoria Ichim
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

8.  Pharmacological Development of Target-Specific Delocalized Lipophilic Cation-Functionalized Carboranes for Cancer Therapy.

Authors:  Eirini D Tseligka; Aikaterini Rova; Elsa P Amanatiadou; Gianpiero Calabrese; John Tsibouklis; Dimitrios G Fatouros; Ioannis S Vizirianakis
Journal:  Pharm Res       Date:  2016-04-26       Impact factor: 4.200

9.  Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.

Authors:  Eleftheria Tsakalozou; Allison M Eckman; Younsoo Bae
Journal:  Biochem Res Int       Date:  2012-07-01

10.  Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays.

Authors:  Richard A Knight; Mikhail Gostev; Sergei Ilisavskii; Anne E Willis; Gerry Melino; Alexey V Antonov
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.